Development of new in-situ hardening and bioactivated composite materials for orthopedic indications:
Gespeichert in:
1. Verfasser: | |
---|---|
Format: | Abschlussarbeit Buch |
Sprache: | English |
Veröffentlicht: |
Göttingen
Cuvillier
2008
|
Ausgabe: | 1. Aufl. |
Schlagworte: | |
Online-Zugang: | Inhaltsverzeichnis |
Beschreibung: | V, 197 S. Ill., graph. Darst. |
ISBN: | 9783867277532 |
Internformat
MARC
LEADER | 00000nam a2200000 c 4500 | ||
---|---|---|---|
001 | BV035163382 | ||
003 | DE-604 | ||
005 | 20090202 | ||
007 | t | ||
008 | 081117s2008 gw ad|| m||| 00||| eng d | ||
015 | |a 08,N44,0739 |2 dnb | ||
016 | 7 | |a 990811468 |2 DE-101 | |
020 | |a 9783867277532 |c Kt. : EUR 29.00 |9 978-3-86727-753-2 | ||
024 | 3 | |a 9783867277532 | |
035 | |a (OCoLC)297584679 | ||
035 | |a (DE-599)DNB990811468 | ||
040 | |a DE-604 |b ger |e rakddb | ||
041 | 0 | |a eng | |
044 | |a gw |c XA-DE-NI | ||
049 | |a DE-19 |a DE-29T |a DE-12 | ||
082 | 0 | |a 617.4710592 |2 22/ger | |
084 | |a 610 |2 sdnb | ||
100 | 1 | |a Pompe, Cornelius |d 1978- |e Verfasser |0 (DE-588)136680224 |4 aut | |
245 | 1 | 0 | |a Development of new in-situ hardening and bioactivated composite materials for orthopedic indications |c vorgelegt von Cornelius Pompe |
250 | |a 1. Aufl. | ||
264 | 1 | |a Göttingen |b Cuvillier |c 2008 | |
300 | |a V, 197 S. |b Ill., graph. Darst. | ||
336 | |b txt |2 rdacontent | ||
337 | |b n |2 rdamedia | ||
338 | |b nc |2 rdacarrier | ||
502 | |a Zugl.: München, Univ., Diss., 2008 | ||
650 | 4 | |a Knochenregeneration - Knochenersatz - Polymilchsäure - Knochen-Morphogenese-Proteine - Bioaktive Verbindungen - Kontrollierte Wirkstofffreisetzung | |
650 | 0 | 7 | |a Knochen-Morphogenese-Proteine |0 (DE-588)4305932-6 |2 gnd |9 rswk-swf |
650 | 0 | 7 | |a Kontrollierte Wirkstofffreisetzung |0 (DE-588)4165181-9 |2 gnd |9 rswk-swf |
650 | 0 | 7 | |a Bioaktive Verbindungen |0 (DE-588)4145589-7 |2 gnd |9 rswk-swf |
650 | 0 | 7 | |a Knochenregeneration |0 (DE-588)4122236-2 |2 gnd |9 rswk-swf |
650 | 0 | 7 | |a Knochenersatz |0 (DE-588)4164283-1 |2 gnd |9 rswk-swf |
650 | 0 | 7 | |a Polymilchsäure |0 (DE-588)4335724-6 |2 gnd |9 rswk-swf |
655 | 7 | |0 (DE-588)4113937-9 |a Hochschulschrift |2 gnd-content | |
689 | 0 | 0 | |a Knochenregeneration |0 (DE-588)4122236-2 |D s |
689 | 0 | 1 | |a Knochenersatz |0 (DE-588)4164283-1 |D s |
689 | 0 | 2 | |a Polymilchsäure |0 (DE-588)4335724-6 |D s |
689 | 0 | 3 | |a Knochen-Morphogenese-Proteine |0 (DE-588)4305932-6 |D s |
689 | 0 | 4 | |a Bioaktive Verbindungen |0 (DE-588)4145589-7 |D s |
689 | 0 | 5 | |a Kontrollierte Wirkstofffreisetzung |0 (DE-588)4165181-9 |D s |
689 | 0 | |5 DE-604 | |
856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016970464&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-016970464 |
Datensatz im Suchindex
_version_ | 1808134915284271104 |
---|---|
adam_text |
TABLE OF CONTENTS 1. INTRODUCTION 1 1.1 BONE MORPHOGENETIC PROTEINS 1
1.1.1 FROM HISTORIC PERSPECTIVE 1 1.1.2 BIOCHEMISTRY 2 1.1.3 BMP
RECEPTOR SIGNALING 4 1.1.4 BIOLOGIE ACTIVITY AND OSTEOINDUETION 5 1.2
STATE OF THE ART IN BONE GROWTH FACTOR DELIVERY 6 1.2.1 DEMANDSON
POTENTIAL BONE SUBSTITUTES 6 1.2.2 APPLIED MATERIALS 7 1.2.2.1 NATURAL
POLYMERS 8 1.2.2.2 SYNTHETIC POLYMERS 8 1.2.2.3 INORGANIC MATERIALS 10
1.2.2.4 COMPOSITE MATERIALS IN BONE AUGMENTATION 11 1.2.2.5 THE WAY TO
INJECTABLE DELIVERY SYSTEMS FOR BONE MORPHOGENETIC PROTEINS 13 2.
DEVELOPMENT OF AN IN-SITU HARDENING BONE SUBSTITUTE FOR MINIMAL INVASIVE
SURGERY 16 2.1 OBJECTIVES 16 2.2 MATERIALS AND METHODS 18 2.2.1
MATERIALS 18 2.2.1.1 RHGDF-5 18 2.2.1.2 ANTIBODIES USED WITHIN THE SCOPE
OF RHGDF-5 QUANTIFICATION 18 2.2.1.3 BIODEGRADABLE POLYMERS 18 2.2.1.4
ADDITIONAL MATERIALS 19 2.2.1.5 OTHER EXCIPIENTS 21 2.2.1.6 BUFFER
COMPONENTS 21 2.2.1.7 REAGENTS AND OTHER SUBSTANCES 22 BIBLIOGRAFISCHE
INFORMATIONEN HTTP://D-NB.INFO/990811468 DIGITALISIERT DURCH TABLE OF
CONTENTS 2.2.2 METHODS 23 2.2.2.1 PHASE TRANSITION OF SS-TRICALCIUM
PHOSPHATE (SS-TCP) 23 2.2.2.2 BIOCEMENT D POWDER PREPARATION 23 2.2.2.2
IFS PREPARATION 23 2.2.2.4 SAMPLE INCUBATION IN PBS 24 2.2.2.5
MECHANICAL TESTING 24 2.2.2.6 VACUUM DRYING OF INCUBATED SPECIMENS 25
2.2.2.7 DIFFERENTIAL SCANNING CALORIMETRY (DSC) 25 2.2.2.S LIGHT
MICROSCOPY AND SOFTWARE BASED QUANTIFICATION OF SUPERFICIAL PORES 25
2.2.2.9 SCANNING ELECTRON MICROSCOPY (SEM) 26 2.2.2.10 MICRO COMPUTED
TOMOGRAPHY (PCT) 26 2.2.2.11 X-RAY POWDER DIFFRACTION (XRD) 26 2.2.2.12
KARL FISCHER TITRATION 26 2.2.2.13 SIZE EXCLUSION CHROMATOGRAPHY WITH
COUPLED MULTI ANGLE LASER LIGHT SCATTERING AND DIFFERENTIAL REFRACTIVE
INDEX DETECTION (SEC-MALLS-DRI) 27 2.2.2.14 DRYING OF RHGDF-5 CONTAINING
PREPARATIONS 28 2.2.2.15 INCUBATION OF RHGDF-5 COATED CT-TCP WITH
VARIOUS ORGANIC PLASTICIZERS 28 2.2.2.16 PHOTOMETRIC QUANTIFICATION OF
OXIDATIVE SPECIES IN ORGANIC PLASTICIZERS 28 2.2.2.17 RHGDF-5 EXTRACTION
AFTER INCUBATION WITH ORGANIC PLASTICIZERS 28 2.2.2.18 RP-HPLC 29
2.2.2.19 LC-ESI-MS 29 2.2.2.20 RHGDF-5 RELEASE FROM IFS 30 2.2.2.21
DETERMINATION OF RHGDF-5 RELEASE FROM IFS BY ELISA 30 2.3 RESULTS AND
DISCUSSION 31 2.3.1 IMPROVEMENT OF THE MECHANICAL PERFORMANCE OF THE IFS
31 2.3.1.1 INVESTIGATIONS ON THE INORGANIC FILIER 31 2.3.1.2 OPTIMIZING
THE POLYMER/CEMENT RATIO 38 2.3.1.3 VARIATION OF THE ORGANIC PLASTICIZER
40 2.3.1. TABLE OF CONTENTS 2.3.4 PLGA STABILITY WITHIN THE IFS 67
2.3.4.1 PURPOSE 67 2.3.4.2 THE IMPACT OF POST-MANUFACTURING VACUUM
DRYING ON DIFFERENT IFS FORMULATIONS 67 2.3.4.3 EVALUATION OF DIFFERENT
DRYING PROCEDURES FOR PEG 400 68 2.3.4.4 SHELF LIFE STUDY OF DIFFERENT
IFS FORMULATIONS 69 2.3.5 /N-WFROBIODEGRADATIONOFTHELFS 78 2.3.6
COMPATIBILITY OF RHGDF-5 WITH VARIOUS ORGANIC PLASTICIZERS 83 2.3.6.1
SOLVENT SCREENING 83 2.3.6.2 INVESTIGATIONS ON DEGRADATION PATHWAYS 84
2.3.6.3 APPROACHES TO REDUCE RHGDF-5 OXIDATION 91 2.3.6.4 CONCLUSION 93
2.4 SUMMARY 94 3. A NEW "PUTTY-LIKE" IN-SITU HARDENING COMPOSITE
MATERIAL 98 3.1 INTRODUCTION 98 3.2 MATERIALS AND METHODS 100 3.2.1
MATERIALS 100 3.2.1.1 RHGDF-5 100 3.2.1.2 ANTIBODIES USED WITHIN THE
SCOPE OF RHGDF-5 QUANTIFICATION 100 3.2.1.3 RHBMP-2 (E.COLI) 100 3.2.1.4
ANTIBODIES USED WITHIN THE SCOPE OF RHBMP-2 (E.COLI) QUANTIFICATION 100
3.2.1.5 RHBMP-2 (CHO) 101 3.2.1.6 BIODEGRADABLE POLYMERS 101 3.2.1.7
OTHER EXCIPIENTS 101 3.2.1.8 BUFFER COMPONENTS 102 3.2.1.9 USEDBUFFERS
103 3.2.1.10 OTHER REAGENTS AND SUBSTANCES 104 3.2.2 METHODS 107 3.2.2.1
CDP1C/CDP2C PUTTY FLUID PREPARATION 107 3.2.2. IV TABLE OF CONTENTS
3.2.2.4 INCUBATION OF CDP1C IN PBS 109 3.2.2.5 VACUUM DRYING OF
INCUBATED SPECIMENS 109 3.2.2.6 DIFFERENTIAL SCANNING CALORIMETRY (DSC)
109 3.2.2.7 SEM/EDX ANALYSIS 109 3.2.2.8 MICRO COMPUTED TOMOGRAPHY (UCT)
110 3.2.2.9 DETERMINATION OF PLGA MOLECULAR WEIGHT BY SEC-MALLS-DRI 110
3.2.2.10 STERILIZATIONBYY-IRRADIATION 110 3.2.2.11 CDP1/CDP2 PREPARATION
111 3.2.2.12 PROTEIN RELEASE FROM CDP1C/CDP2CFORELISAEVALUATION 111
3.2.2.13 DETERMINATION OF RHGDF-5 RELEASE BY ELISA 111 3.2.2.14
DETERMINATION OF RHBMP-2 (E.CO/0 RELEASE IN A-MEM/10% FCS BY ELISA 111
3.2.2.15 DETERMINATION OF RHBMP-2 (CHO) RELEASE IN A-MEM/10% FCS BY
ELISA 112 3.2.2.16 EXTRACTION FROM NON RELEASED RHGDF-5 FRACTIONS FROM
CDP1C 112 3.2.2.17 RHGDF-5 CHARACTERIZATION AND QUANTIFICATION BY
RP-HPLC 112 3.2.2.18 RHBMP-2 QUANTIFICATION BY RP-HPLC 113 3.2.2.19
RHGDF-5 ANALYSIS BY SEC 114 3.2.2.20 RHGDF-5 ANALYSIS BY LDS-PAGE 114
3.2.2.21 RHGDF-5 ANALYSIS BY IEF 114 3.2.2.22 RHGDF-5 RELEASE FROM CDP1C
FOR ALP ASSAY 115 3.2.2.23 CULTIVATION OF MURINE STROMAL MCHT-1/26 CELLS
115 3.2.2.24 PREPARATION OF MURINE STROMAL MCHT-1/26 CELLS FOR ALP ASSAY
115 3.2.2.25 ALP ASSAY 116 3.2.2.26 CDPICBIOCOMPATIBILITYSTUDY/N-IWO 116
3.3 RESULTSAND DISCUSSION 117 3.3.1 AN IN-VITRO MODEL FOR RHBMP-2
RELEASE FROM SOME CDP2C VARIANTS 117 3.3.1.1 OBJECTIVES 117 3.3.1. 5.
REFERENCES 175 TABLE OF CONTENTS 3.3.2.1 INTRODUCTION 131 3.3.2.2
MOLECULAR WEIGHT AND MASS LOSS 131 3.3.2.3 THERMAL BEHAVIOR 134 3.3.2.4
RESIDUAL PEG 400 CONTENT 136 3.3.2.5 MORPHOLOGY 137 3.3.2.6 CONCLUSION
138 3.3.3 IN-VITRO RHGDF-5 RELEASE 139 3.3.3.1 INTRODUCTION 139 3.3.3.2
RHGDF-5 RELEASE FROM CDP1C 139 3.3.3.3 EDX ANALYSIS OF CDP1C VARIANTS
AFTER 24 H OF INCUBATION IN PBS 141 3.3.3.4 VISUALIZATION OF PHASE
INVERSION 143 3.3.3.5 SEM ANALYSIS CDP1C VARIANTS AFTER 24 H OF
INCUBATION IN PBS 145 3.3.3.6 CONDUSION 145 3.3.4 CHARACTERIZATION OF
NON RELEASED RHGDF-5 FRACTIONS 146 3.3.4.1 INTRODUCTION 146 3.3.4.2
RP-HPLC OF NON RELEASED RHGDF-5 FRACTIONS 146 3.3.4.3 IEF OF NON
RELEASED RHGDF-5 FRACTIONS 147 3.3.4.4 LDS-PAGE OF NON RELEASED
FRACTIONS 148 3.3.4.5 SEC ANALYSIS OF NON RELEASED FRACTIONS 150 3.3.4.5
ALKALINE PHOSPHATASE ACTIVITY OF RELEASED RHGDF-5 151 3.3.4.6 CONCLUSION
153 3.3.5 EFFECTS OF STERILIZATION ON CDPICPUTTYFLUID FORMULATIONS 153
3.3.5.1 INTRODUCTION 153 3.3.5.2 THE IMPACT OF Y-IRRADIATION ON PLGA
MOLECULAR WEIGHT 156 3.3.5.3 THE IMPACT OF Y-IRRADAITION ON RHGDF-5
RELEASE 163 3.3.5.4 CONDUSION 166 3.3.6 BIOCOMPATIBILITY OF CDP1C 168
3.4 SUMMARY 169 4. FINAL CONCLUSION 172 |
adam_txt |
TABLE OF CONTENTS 1. INTRODUCTION 1 1.1 BONE MORPHOGENETIC PROTEINS 1
1.1.1 FROM HISTORIC PERSPECTIVE 1 1.1.2 BIOCHEMISTRY 2 1.1.3 BMP
RECEPTOR SIGNALING 4 1.1.4 BIOLOGIE ACTIVITY AND OSTEOINDUETION 5 1.2
STATE OF THE ART IN BONE GROWTH FACTOR DELIVERY 6 1.2.1 DEMANDSON
POTENTIAL BONE SUBSTITUTES 6 1.2.2 APPLIED MATERIALS 7 1.2.2.1 NATURAL
POLYMERS 8 1.2.2.2 SYNTHETIC POLYMERS 8 1.2.2.3 INORGANIC MATERIALS 10
1.2.2.4 COMPOSITE MATERIALS IN BONE AUGMENTATION 11 1.2.2.5 THE WAY TO
INJECTABLE DELIVERY SYSTEMS FOR BONE MORPHOGENETIC PROTEINS 13 2.
DEVELOPMENT OF AN IN-SITU HARDENING BONE SUBSTITUTE FOR MINIMAL INVASIVE
SURGERY 16 2.1 OBJECTIVES 16 2.2 MATERIALS AND METHODS 18 2.2.1
MATERIALS 18 2.2.1.1 RHGDF-5 18 2.2.1.2 ANTIBODIES USED WITHIN THE SCOPE
OF RHGDF-5 QUANTIFICATION 18 2.2.1.3 BIODEGRADABLE POLYMERS 18 2.2.1.4
ADDITIONAL MATERIALS 19 2.2.1.5 OTHER EXCIPIENTS 21 2.2.1.6 BUFFER
COMPONENTS 21 2.2.1.7 REAGENTS AND OTHER SUBSTANCES 22 BIBLIOGRAFISCHE
INFORMATIONEN HTTP://D-NB.INFO/990811468 DIGITALISIERT DURCH TABLE OF
CONTENTS 2.2.2 METHODS 23 2.2.2.1 PHASE TRANSITION OF SS-TRICALCIUM
PHOSPHATE (SS-TCP) 23 2.2.2.2 BIOCEMENT D POWDER PREPARATION 23 2.2.2.2
IFS PREPARATION 23 2.2.2.4 SAMPLE INCUBATION IN PBS 24 2.2.2.5
MECHANICAL TESTING 24 2.2.2.6 VACUUM DRYING OF INCUBATED SPECIMENS 25
2.2.2.7 DIFFERENTIAL SCANNING CALORIMETRY (DSC) 25 2.2.2.S LIGHT
MICROSCOPY AND SOFTWARE BASED QUANTIFICATION OF SUPERFICIAL PORES 25
2.2.2.9 SCANNING ELECTRON MICROSCOPY (SEM) 26 2.2.2.10 MICRO COMPUTED
TOMOGRAPHY (PCT) 26 2.2.2.11 X-RAY POWDER DIFFRACTION (XRD) 26 2.2.2.12
KARL FISCHER TITRATION 26 2.2.2.13 SIZE EXCLUSION CHROMATOGRAPHY WITH
COUPLED MULTI ANGLE LASER LIGHT SCATTERING AND DIFFERENTIAL REFRACTIVE
INDEX DETECTION (SEC-MALLS-DRI) 27 2.2.2.14 DRYING OF RHGDF-5 CONTAINING
PREPARATIONS 28 2.2.2.15 INCUBATION OF RHGDF-5 COATED CT-TCP WITH
VARIOUS ORGANIC PLASTICIZERS 28 2.2.2.16 PHOTOMETRIC QUANTIFICATION OF
OXIDATIVE SPECIES IN ORGANIC PLASTICIZERS 28 2.2.2.17 RHGDF-5 EXTRACTION
AFTER INCUBATION WITH ORGANIC PLASTICIZERS 28 2.2.2.18 RP-HPLC 29
2.2.2.19 LC-ESI-MS 29 2.2.2.20 RHGDF-5 RELEASE FROM IFS 30 2.2.2.21
DETERMINATION OF RHGDF-5 RELEASE FROM IFS BY ELISA 30 2.3 RESULTS AND
DISCUSSION 31 2.3.1 IMPROVEMENT OF THE MECHANICAL PERFORMANCE OF THE IFS
31 2.3.1.1 INVESTIGATIONS ON THE INORGANIC FILIER 31 2.3.1.2 OPTIMIZING
THE POLYMER/CEMENT RATIO 38 2.3.1.3 VARIATION OF THE ORGANIC PLASTICIZER
40 2.3.1. TABLE OF CONTENTS 2.3.4 PLGA STABILITY WITHIN THE IFS 67
2.3.4.1 PURPOSE 67 2.3.4.2 THE IMPACT OF POST-MANUFACTURING VACUUM
DRYING ON DIFFERENT IFS FORMULATIONS 67 2.3.4.3 EVALUATION OF DIFFERENT
DRYING PROCEDURES FOR PEG 400 68 2.3.4.4 SHELF LIFE STUDY OF DIFFERENT
IFS FORMULATIONS 69 2.3.5 /N-WFROBIODEGRADATIONOFTHELFS 78 2.3.6
COMPATIBILITY OF RHGDF-5 WITH VARIOUS ORGANIC PLASTICIZERS 83 2.3.6.1
SOLVENT SCREENING 83 2.3.6.2 INVESTIGATIONS ON DEGRADATION PATHWAYS 84
2.3.6.3 APPROACHES TO REDUCE RHGDF-5 OXIDATION 91 2.3.6.4 CONCLUSION 93
2.4 SUMMARY 94 3. A NEW "PUTTY-LIKE" IN-SITU HARDENING COMPOSITE
MATERIAL 98 3.1 INTRODUCTION 98 3.2 MATERIALS AND METHODS 100 3.2.1
MATERIALS 100 3.2.1.1 RHGDF-5 100 3.2.1.2 ANTIBODIES USED WITHIN THE
SCOPE OF RHGDF-5 QUANTIFICATION 100 3.2.1.3 RHBMP-2 (E.COLI) 100 3.2.1.4
ANTIBODIES USED WITHIN THE SCOPE OF RHBMP-2 (E.COLI) QUANTIFICATION 100
3.2.1.5 RHBMP-2 (CHO) 101 3.2.1.6 BIODEGRADABLE POLYMERS 101 3.2.1.7
OTHER EXCIPIENTS 101 3.2.1.8 BUFFER COMPONENTS 102 3.2.1.9 USEDBUFFERS
103 3.2.1.10 OTHER REAGENTS AND SUBSTANCES 104 3.2.2 METHODS 107 3.2.2.1
CDP1C/CDP2C PUTTY FLUID PREPARATION 107 3.2.2. IV TABLE OF CONTENTS
3.2.2.4 INCUBATION OF CDP1C IN PBS 109 3.2.2.5 VACUUM DRYING OF
INCUBATED SPECIMENS 109 3.2.2.6 DIFFERENTIAL SCANNING CALORIMETRY (DSC)
109 3.2.2.7 SEM/EDX ANALYSIS 109 3.2.2.8 MICRO COMPUTED TOMOGRAPHY (UCT)
110 3.2.2.9 DETERMINATION OF PLGA MOLECULAR WEIGHT BY SEC-MALLS-DRI 110
3.2.2.10 STERILIZATIONBYY-IRRADIATION 110 3.2.2.11 CDP1/CDP2 PREPARATION
111 3.2.2.12 PROTEIN RELEASE FROM CDP1C/CDP2CFORELISAEVALUATION 111
3.2.2.13 DETERMINATION OF RHGDF-5 RELEASE BY ELISA 111 3.2.2.14
DETERMINATION OF RHBMP-2 (E.CO/0 RELEASE IN A-MEM/10% FCS BY ELISA 111
3.2.2.15 DETERMINATION OF RHBMP-2 (CHO) RELEASE IN A-MEM/10% FCS BY
ELISA 112 3.2.2.16 EXTRACTION FROM NON RELEASED RHGDF-5 FRACTIONS FROM
CDP1C 112 3.2.2.17 RHGDF-5 CHARACTERIZATION AND QUANTIFICATION BY
RP-HPLC 112 3.2.2.18 RHBMP-2 QUANTIFICATION BY RP-HPLC 113 3.2.2.19
RHGDF-5 ANALYSIS BY SEC 114 3.2.2.20 RHGDF-5 ANALYSIS BY LDS-PAGE 114
3.2.2.21 RHGDF-5 ANALYSIS BY IEF 114 3.2.2.22 RHGDF-5 RELEASE FROM CDP1C
FOR ALP ASSAY 115 3.2.2.23 CULTIVATION OF MURINE STROMAL MCHT-1/26 CELLS
115 3.2.2.24 PREPARATION OF MURINE STROMAL MCHT-1/26 CELLS FOR ALP ASSAY
115 3.2.2.25 ALP ASSAY 116 3.2.2.26 CDPICBIOCOMPATIBILITYSTUDY/N-IWO 116
3.3 RESULTSAND DISCUSSION 117 3.3.1 AN IN-VITRO MODEL FOR RHBMP-2
RELEASE FROM SOME CDP2C VARIANTS 117 3.3.1.1 OBJECTIVES 117 3.3.1. 5.
REFERENCES 175 TABLE OF CONTENTS 3.3.2.1 INTRODUCTION 131 3.3.2.2
MOLECULAR WEIGHT AND MASS LOSS 131 3.3.2.3 THERMAL BEHAVIOR 134 3.3.2.4
RESIDUAL PEG 400 CONTENT 136 3.3.2.5 MORPHOLOGY 137 3.3.2.6 CONCLUSION
138 3.3.3 IN-VITRO RHGDF-5 RELEASE 139 3.3.3.1 INTRODUCTION 139 3.3.3.2
RHGDF-5 RELEASE FROM CDP1C 139 3.3.3.3 EDX ANALYSIS OF CDP1C VARIANTS
AFTER 24 H OF INCUBATION IN PBS 141 3.3.3.4 VISUALIZATION OF PHASE
INVERSION 143 3.3.3.5 SEM ANALYSIS CDP1C VARIANTS AFTER 24 H OF
INCUBATION IN PBS 145 3.3.3.6 CONDUSION 145 3.3.4 CHARACTERIZATION OF
NON RELEASED RHGDF-5 FRACTIONS 146 3.3.4.1 INTRODUCTION 146 3.3.4.2
RP-HPLC OF NON RELEASED RHGDF-5 FRACTIONS 146 3.3.4.3 IEF OF NON
RELEASED RHGDF-5 FRACTIONS 147 3.3.4.4 LDS-PAGE OF NON RELEASED
FRACTIONS 148 3.3.4.5 SEC ANALYSIS OF NON RELEASED FRACTIONS 150 3.3.4.5
ALKALINE PHOSPHATASE ACTIVITY OF RELEASED RHGDF-5 151 3.3.4.6 CONCLUSION
153 3.3.5 EFFECTS OF STERILIZATION ON CDPICPUTTYFLUID FORMULATIONS 153
3.3.5.1 INTRODUCTION 153 3.3.5.2 THE IMPACT OF Y-IRRADIATION ON PLGA
MOLECULAR WEIGHT 156 3.3.5.3 THE IMPACT OF Y-IRRADAITION ON RHGDF-5
RELEASE 163 3.3.5.4 CONDUSION 166 3.3.6 BIOCOMPATIBILITY OF CDP1C 168
3.4 SUMMARY 169 4. FINAL CONCLUSION 172 |
any_adam_object | 1 |
any_adam_object_boolean | 1 |
author | Pompe, Cornelius 1978- |
author_GND | (DE-588)136680224 |
author_facet | Pompe, Cornelius 1978- |
author_role | aut |
author_sort | Pompe, Cornelius 1978- |
author_variant | c p cp |
building | Verbundindex |
bvnumber | BV035163382 |
ctrlnum | (OCoLC)297584679 (DE-599)DNB990811468 |
dewey-full | 617.4710592 |
dewey-hundreds | 600 - Technology (Applied sciences) |
dewey-ones | 617 - Surgery & related medical specialties |
dewey-raw | 617.4710592 |
dewey-search | 617.4710592 |
dewey-sort | 3617.4710592 |
dewey-tens | 610 - Medicine and health |
discipline | Medizin |
discipline_str_mv | Medizin |
edition | 1. Aufl. |
format | Thesis Book |
fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000 c 4500</leader><controlfield tag="001">BV035163382</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20090202</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">081117s2008 gw ad|| m||| 00||| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">08,N44,0739</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">990811468</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783867277532</subfield><subfield code="c">Kt. : EUR 29.00</subfield><subfield code="9">978-3-86727-753-2</subfield></datafield><datafield tag="024" ind1="3" ind2=" "><subfield code="a">9783867277532</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)297584679</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB990811468</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-NI</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield><subfield code="a">DE-29T</subfield><subfield code="a">DE-12</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">617.4710592</subfield><subfield code="2">22/ger</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Pompe, Cornelius</subfield><subfield code="d">1978-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)136680224</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Development of new in-situ hardening and bioactivated composite materials for orthopedic indications</subfield><subfield code="c">vorgelegt von Cornelius Pompe</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1. Aufl.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Göttingen</subfield><subfield code="b">Cuvillier</subfield><subfield code="c">2008</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">V, 197 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="502" ind1=" " ind2=" "><subfield code="a">Zugl.: München, Univ., Diss., 2008</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Knochenregeneration - Knochenersatz - Polymilchsäure - Knochen-Morphogenese-Proteine - Bioaktive Verbindungen - Kontrollierte Wirkstofffreisetzung</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Knochen-Morphogenese-Proteine</subfield><subfield code="0">(DE-588)4305932-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Kontrollierte Wirkstofffreisetzung</subfield><subfield code="0">(DE-588)4165181-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Bioaktive Verbindungen</subfield><subfield code="0">(DE-588)4145589-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Knochenregeneration</subfield><subfield code="0">(DE-588)4122236-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Knochenersatz</subfield><subfield code="0">(DE-588)4164283-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Polymilchsäure</subfield><subfield code="0">(DE-588)4335724-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4113937-9</subfield><subfield code="a">Hochschulschrift</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Knochenregeneration</subfield><subfield code="0">(DE-588)4122236-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Knochenersatz</subfield><subfield code="0">(DE-588)4164283-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Polymilchsäure</subfield><subfield code="0">(DE-588)4335724-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Knochen-Morphogenese-Proteine</subfield><subfield code="0">(DE-588)4305932-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="4"><subfield code="a">Bioaktive Verbindungen</subfield><subfield code="0">(DE-588)4145589-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="5"><subfield code="a">Kontrollierte Wirkstofffreisetzung</subfield><subfield code="0">(DE-588)4165181-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016970464&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-016970464</subfield></datafield></record></collection> |
genre | (DE-588)4113937-9 Hochschulschrift gnd-content |
genre_facet | Hochschulschrift |
id | DE-604.BV035163382 |
illustrated | Illustrated |
index_date | 2024-07-02T22:51:31Z |
indexdate | 2024-08-23T00:10:28Z |
institution | BVB |
isbn | 9783867277532 |
language | English |
oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-016970464 |
oclc_num | 297584679 |
open_access_boolean | |
owner | DE-19 DE-BY-UBM DE-29T DE-12 |
owner_facet | DE-19 DE-BY-UBM DE-29T DE-12 |
physical | V, 197 S. Ill., graph. Darst. |
publishDate | 2008 |
publishDateSearch | 2008 |
publishDateSort | 2008 |
publisher | Cuvillier |
record_format | marc |
spelling | Pompe, Cornelius 1978- Verfasser (DE-588)136680224 aut Development of new in-situ hardening and bioactivated composite materials for orthopedic indications vorgelegt von Cornelius Pompe 1. Aufl. Göttingen Cuvillier 2008 V, 197 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Zugl.: München, Univ., Diss., 2008 Knochenregeneration - Knochenersatz - Polymilchsäure - Knochen-Morphogenese-Proteine - Bioaktive Verbindungen - Kontrollierte Wirkstofffreisetzung Knochen-Morphogenese-Proteine (DE-588)4305932-6 gnd rswk-swf Kontrollierte Wirkstofffreisetzung (DE-588)4165181-9 gnd rswk-swf Bioaktive Verbindungen (DE-588)4145589-7 gnd rswk-swf Knochenregeneration (DE-588)4122236-2 gnd rswk-swf Knochenersatz (DE-588)4164283-1 gnd rswk-swf Polymilchsäure (DE-588)4335724-6 gnd rswk-swf (DE-588)4113937-9 Hochschulschrift gnd-content Knochenregeneration (DE-588)4122236-2 s Knochenersatz (DE-588)4164283-1 s Polymilchsäure (DE-588)4335724-6 s Knochen-Morphogenese-Proteine (DE-588)4305932-6 s Bioaktive Verbindungen (DE-588)4145589-7 s Kontrollierte Wirkstofffreisetzung (DE-588)4165181-9 s DE-604 DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016970464&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
spellingShingle | Pompe, Cornelius 1978- Development of new in-situ hardening and bioactivated composite materials for orthopedic indications Knochenregeneration - Knochenersatz - Polymilchsäure - Knochen-Morphogenese-Proteine - Bioaktive Verbindungen - Kontrollierte Wirkstofffreisetzung Knochen-Morphogenese-Proteine (DE-588)4305932-6 gnd Kontrollierte Wirkstofffreisetzung (DE-588)4165181-9 gnd Bioaktive Verbindungen (DE-588)4145589-7 gnd Knochenregeneration (DE-588)4122236-2 gnd Knochenersatz (DE-588)4164283-1 gnd Polymilchsäure (DE-588)4335724-6 gnd |
subject_GND | (DE-588)4305932-6 (DE-588)4165181-9 (DE-588)4145589-7 (DE-588)4122236-2 (DE-588)4164283-1 (DE-588)4335724-6 (DE-588)4113937-9 |
title | Development of new in-situ hardening and bioactivated composite materials for orthopedic indications |
title_auth | Development of new in-situ hardening and bioactivated composite materials for orthopedic indications |
title_exact_search | Development of new in-situ hardening and bioactivated composite materials for orthopedic indications |
title_exact_search_txtP | Development of new in-situ hardening and bioactivated composite materials for orthopedic indications |
title_full | Development of new in-situ hardening and bioactivated composite materials for orthopedic indications vorgelegt von Cornelius Pompe |
title_fullStr | Development of new in-situ hardening and bioactivated composite materials for orthopedic indications vorgelegt von Cornelius Pompe |
title_full_unstemmed | Development of new in-situ hardening and bioactivated composite materials for orthopedic indications vorgelegt von Cornelius Pompe |
title_short | Development of new in-situ hardening and bioactivated composite materials for orthopedic indications |
title_sort | development of new in situ hardening and bioactivated composite materials for orthopedic indications |
topic | Knochenregeneration - Knochenersatz - Polymilchsäure - Knochen-Morphogenese-Proteine - Bioaktive Verbindungen - Kontrollierte Wirkstofffreisetzung Knochen-Morphogenese-Proteine (DE-588)4305932-6 gnd Kontrollierte Wirkstofffreisetzung (DE-588)4165181-9 gnd Bioaktive Verbindungen (DE-588)4145589-7 gnd Knochenregeneration (DE-588)4122236-2 gnd Knochenersatz (DE-588)4164283-1 gnd Polymilchsäure (DE-588)4335724-6 gnd |
topic_facet | Knochenregeneration - Knochenersatz - Polymilchsäure - Knochen-Morphogenese-Proteine - Bioaktive Verbindungen - Kontrollierte Wirkstofffreisetzung Knochen-Morphogenese-Proteine Kontrollierte Wirkstofffreisetzung Bioaktive Verbindungen Knochenregeneration Knochenersatz Polymilchsäure Hochschulschrift |
url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016970464&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
work_keys_str_mv | AT pompecornelius developmentofnewinsituhardeningandbioactivatedcompositematerialsfororthopedicindications |